Val-HeFT

Val-HeFT

Valsartan heart failure trial Cardiology A multinational M&M study investigating valsartan use with standard therapy–eg, ACE inhibitors, in Pts with previously treated and untreated CHF. See Valsartan.
Mentioned in ?
References in periodicals archive ?
These data emphasize that GDF-15 reflects a disease pathway that is not fully addressed by the therapies prescribed to the patients in Val-HeFT (60).
However, patients in the Val-HeFT trial who took ARBs with an ACE inhibitor and a [beta]-blocker had worse outcomes.
However, patients in Val-HeFT who took ARBs with an ACE inhibitor and a [beta]blocker had worse outcomes.
The most common side effects in Val-HeFT were dizziness and hypotension.
Valsartan was added to ACE inhibition in most patients randomized to valsartan in Val-Heft (93%), compared with only 13% of patients in TIME-CHF.
Val-HeFT demonstrated that Diovan significantly reduced combined all-cause mortality and morbidity in patients with heart failure also taking usual therapy.
4] Nonstandard abbreviations: hs-cTnT, highly sensitive cardiac troponin T (assay); hs-cTnI, highly sensitive cardiac troponin I (assay); MI, myocardial infarction; hs-CRP, high-sensitivity C-reactive protein; Val-HeFT, Valsartan Heart Failure Trial; PEACE, Prevention of Events with Angiotensin Converting Enzyme Inhibition; NT-proBNP, N-terminal pro-B-type natriuretic peptide; ED, emergency department.
The Val-HeFT data also clearly underscore the importance of AF as an end point to be avoided.
The Val-Heft study reported similar results in terms of additive prognostic information by using hscTnT measurement and a natriuretic peptide (14).
First came Val-HeFT, a study showing that valsartan didn't reduce mortality, and which suggested that combining the ARB with an ACE inhibitor and a [beta]-blocker might actually be harmful.